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A randomized trial of cyclosporine in steroid-resistant idiopathic ne-
phrotic syndrome. To compare the efficacy (induction of remission) and
safety of cyclosporine (CsA) with those of supportive therapy in
patients with steroid-resistant idiopathic nephrotic syndrome (INS), we
organized an open, prospective, randomized, multicentric, controlled
study for parallel groups, stratified for adults and children. Forty-five
patients with steroid-resistant INS were randomly assigned to support-
ive therapy or CsA (5 mg/kg/day for adults, 6 mg/kg/day for children) for
six months, then tapered off by 25% every two months until complete
discontinuation. Four patients were lost to follow-up. During the first
year 13/22 CsA-treated patients versus three of 19 controls attained
remission of the nephrotic syndrome (P <0.001). A symptom score was
assessed at time 0 and at six months. The mean score significantly
decreased in the CsA group (P < 0.001), but remained unchanged in the
controls. At month 6 the mean urinary protein excretion, the mean
serum proteins and plasma cholesterol had significantly improved in the
CsA group but were not changed in the controls. There were no
significant differences in serum creatinine and creatinine clearance
between treatments (interaction time* treatments, P = 0.089 and P =
0.935, respectively) at month 6 versus basal. The CsA-related side-
effects were mild; no significant difference in blood pressure between
the two groups was seen at any time. This study shows that CsA can
bring about remission in some 60% of patients with steroid-resistant
INS. In patients with normal renal function and without severe hyper-
tension, CsA at the therapeutic scheme adopted did not produce severe
renal or extrarenal toxicity.
The term idiopathic nephrotic syndrome (INS) encompasses
a spectrum of clinicopathological entities. Some investigators
divide INS in different subgroups on the basis of the histological
findings at renal biopsy, mainly minimal change disease (MCD)
or focal segmental glomeruloscierosis (FSGS). Others, how-
ever, think that the response to corticosteroids is even more
important than the initial histological picture in predicting the
long-term renal outcome of patients with INS and recommend
dividing patients with INS into steroid-sensitive and steroid-
resistant [1, 2]. Patients who respond to steroids generally
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maintain normal renal function over time, while patients with
steroid-resistant INS show FSGS sooner or later in renal biopsy
and often progress to end-stage renal disease.
Recently, cyclosporine (CsA) has been used to treat INS.
The drug was able to cause disappearance of proteinuria in most
steroid-sensitive patients [3—7]. The results in patients with
steroid-resistant INS have been more controversial. Some
investigators found CsA not useful in this condition [8] and
others reported worsening of renal lesions in a few patients
given CsA [9]. Conversely, reviews of the literature show that
CsA caused remission of the proteinuria in a good proportion of
patients [10, 111 without significantly changing serum creati-
nine, at least in patients who started treatment with normal
renal function [12]. Unfortunately, none of the published stud-
ies conducted with CsA in INS have been controlled. The
criteria for selection, the doses of CsA, the duration of the
treatment and the length of follow-up varied considerably in the
different studies and this can well have biased the final conclu-
sions.
To better assess the effects of CsA in patients with steroid-
resistant INS, we started a prospective, controlled, multicenter
trial in 1986. Patients who did not respond to a standard
treatment with prednisone were randomly assigned to either
symptomatic therapy or CsA, given at a "full" dose for six
months and then gradually tapered off over the following six
months.
Methods
Eligibility criteria
Patients with nephrotic syndrome (see Definitions) and cre-
atinine clearance greater than 80 ml/min/l .73 m2 for children or
60 ml/min/1.73 m2 for adults and with renal biopsies showing
either MCD or FSGS were considered for the study. Patients
younger than 2 or older than 65 years, those with nephropathy
secondary to a well identified cause, patients with neoplasia,
hereditary angioedema, gastrointestinal malabsorption, con-
comitant infection or liver dysfunction, pregnant women, non-
compliant patients, drug or alcohol abusers, patients requiring
antiepileptic drugs and those with diastolic blood pressure
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higher than 95 mm Hg, if untreated, or higher than 90 mm Hg if
on antihypertensive treatment, were not admitted to the study.
Patients who were given immunosuppressive agents or cyclo-
sporine in the previous 12 months were also excluded from the
study.
Adult patients who met the eligibility criteria were given 1
mg/kg/day prednisone for six weeks and children 60 mg/m2/day
for five weeks. Only patients who did not have either complete
or partial remission of the nephrotic syndrome were admitted to
the study.
Definitions
Patients younger than 16 years were considered children,
those older than 16 adults. The nephrotic syndrome was defined
by a proteinuria greater than 40 mg/m2/hr for children or greater
than 3.5 g/day for adults, with variable edema. Corticosteroid
resistance was defined as the persistence of the nephrotic
syndrome after six weeks on prednisone (1 mg/kg/day) for
adults or five weeks of prednisone (60 mg/m2/day) for children.
A partial remission was defined as proteinuria less than 40
mg/m2/hr (children) or 3.5 g/day (adults) during three non-
consecutive days. A complete remission was defined as pro-
teinuria less than 4 mglm2/hr (children) or 0.2 g/day (adults), on
three different non-consecutive days. The time for response
was the number of days from the start of treatment to the first
day of complete remission (or of partial remission, if complete
remission was not obtained). A relapse of nonnephrotic pro-
teinuria was defined in those patients who had attained a
complete remission of proteinuria as the reappearance of pro-
teinuria greater than 4 mg/m2/hr (children) or 0.2 g/day (adults)
for at least two weeks. A relapse of the nephrotic syndrome was
defined in those patients who had attained complete or partial
remission as the reappearance of proteinuria greater than 40
mg/m2/hr (children) or 3.5 g/day (adults) for at least two weeks.
Arterial hypertension was defined as a diastolic blood pressure
higher than 95 mm Hg in adults and equal to or greater than the
95th percentile for age in children, as assessed in at least two
consecutive occasions by the attending physician [13, 14]. The
histological diagnosis of the renal disease was based on the
criteria of the WHO [15].The presence of even one glomerulus
with segmentary hyalinosis was sufficient for a diagnosis of
FSGS. Vascular lesions and interstitial fibrosis with tubular
atrophy were classified as present or absent. Small areas of
tubular atrophy or interstitial fibrosis, that constituted less than
10% of the biopsy specimen, were considered to be negative.
Randomization
The research protocol was approved by our institutional
review board. This study was an open, randomized trial. A
by-center stratified randomization was not deemed suitable due
to the little sample size. After eligibility criteria were met and
the patients' (or parents') informed consent was obtained, each
patient was randomly assigned to either cyclosporine or sup-
portive therapy within each stratum (adults or children).
For all patients, the indication for the therapy was contained
in sealed, completely opaque envelopes numbered in sequence
according to a table of random numbers. The enrollment of new
patients ended in 1989, when the planned number of 20 patients
in each treatment group was reached. This was considered
sufficient to have a power of 0.80 for demonstrating a 0.05
increase in the cumulative proportion of clinical response in the
control group versus a 0.40 increase in the CsA group at month
6, using a two-tailed statistical test performed at 0.05 signifi-
cance level. Therefore we performed the final analysis.
Treatment
Experimental group. Cyclosporine was administered orally,
at the initial dose of 5 mg/kg/day to adults and 6 mg/kg/day to
children, divided in two doses (before breakfast and before
supper). The doses were then adjusted to maintain the trough
blood levels of CsA between 250 and 600 ng/mI, as measured by
the non-specific polyclonal RIA method [161 in blood samples
taken 10 to 14 hours after the last administration. Trough blood
levels were measured every week in the first month, every two
weeks in the second and the third month, monthly until the
sixth month and then every two months until the end of the
year. Further measurements were made if there was a relapse of
the nephrotic syndrome or serum creatinine increased more
than 30% over the baseline values. The "adjusted" dose was
reduced by 25 to 50% if there was: an increase in serum
creatinine to 30% or more over the basal values; an increase in
serum potassium level to 6 mEq/liter or more; a doubling of the
levels of serum transaminases, alkaline phosphatase, bilirubin
and/or gammaglutamyltranspeptidase; an arterial hypertension
refractory to treatment; or other severe side effects. According
to the protocol if the reduction of the dose did not normalize the
abnormal parameters within two weeks, CsA had to be further
reduced by 25 to 50%, and if abnormalities still persisted after
two weeks, CsA had to be definitively stopped.
After the sixth month, CsA was stopped in patients who had
not obtained either complete or partial remission. For patients
who responded, the dose was reduced by 25% every two
months, independently of the blood levels of CsA, so that CsA
was stopped by the end of the year.
Control group. Patients were given only supportive treatment
for one year. A "rescue treatment" with corticosteroids, at
doses and for the periods established by the attending nephrol-
ogist, was allowed for those patients who showed rapidly
progressive renal failure or a devastating nephrotic syndrome.
This choice was made on the assumption that some few patients
who have not responded to the initial course of prednisone
might take advantage by a more prolonged administration of
corticosteroids [17]. These patients were still considered in the
statistical analysis as controls.
Supportive therapy. With the exception of "rescue treat-
ments," corticosteroid and immunosuppressive agents were
forbidden. The clinicians were asked not to use erythromycin,
cotrimoxazole, aminoglycosides, converting enzyme inhibitors,
non-steroidal antiinfiammatory drugs and/or anti-epileptic drugs
which could affect either CsA metabolism or urinary protein
excretion. Other treatments could be given. Patients were
asked to reduce their salt intake. Protein intake was free.
Efforts were made to give similar supportive therapies to each
of the two groups.
Clinical and laboratoiy investigations. The frequency of
follow-up and of laboratory tests and procedures was the same
for both groups (every week for the first month, every 2 weeks
in the second and the third months, every month until the sixth
month and then every 2 months until the end of the follow-up).
The patients were examined whenever they came for laboratory
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analyses or reported any symptoms. At each visit, blood
pressure was measured twice with a standard mercury sphyg-
momanometer.
The following signs or symptoms were arbitrarily scored from
0 to + + + and summed to construct a symptom score: edema,
weakness, anorexia, nausea, diarrhea, depression. The follow-
ing biochemical parameters were measured at all controls:
leukocyte, erythrocyte and platelet counts; serum creatinine;
creatinine clearance assessed by 24 hour urine collection;
urinary excretion of protein (mglm2/hr); azotemia; serum albu-
min; plasma cholesterol; glucose; serum uric acid; transami-
nases; total bilirubin; alkaline phosphatase; gammaglutamyl-
traspeptidase; sodium, potassium, and magnesium.
Statistical analysis
The distribution of categorical variables such as sex, stratum
(adult-child), the diagnosis after renal biopsy (MCN, FSGS),
the outcome (prevalence of partial and complete remission—no
remission), the presence of hypertension or not, was compared
by the chi square test. For the continuous variables (laboratory
parameters), changes from baseline within and between treat-
ment groups were evaluated by means of the t-tests for paired
and unpaired data. To analyze the overall proteinuria data
without dividing the sample into two subgroups, we trans-
formed the proteinuria of the adult patients, in glday, into the
unit of measurement for the children's proteinuria, mg/m2/hr.
To obtain normal distribution, proteinuria, serum creatinine,
creatinine clearance were transformed into log values. A mixed
factorial ANOVA was performed on these transformed data,
without considering the "center" as a factor. Since the little
number of patients per center, the "among centers" factor has
not been taken into account in the analysis, and the related
variability is therefore confounded with the "among patients"
one. Patients who did not complete the treatment were included
in the analysis according to the intention-to-treat principle. The
effect of treatment on the time of partial or complete remission
as first event was analyzed by a univariate approach, using
"survival" curves calculated according to the Kaplan-Meier
product limit estimate [181; differences in survival distributions
were assessed by the log-rank test.
The analysis was performed with SAS software under PC-
DOS.
Results
Of 45 patients admitted to the study, four were dropped
within the first 45 days after assignment. One woman, aged 20
years, assigned to CsA, had a creatinine clearance of less than
60 ml/min/l .73 m2 and uncontrolled hypertension at the moment
of random assignment. Treatment was therefore stopped after a
few days because the patient did not meet the criteria for
inclusion. Three children (two girls, aged 7 and 10 years, one
boy aged 9) assigned to the control group were dropped because
they did not come for the required visits.
Of the remaining 41 patients, 22 were on CsA and 19 on
symptomatic treatment. At the time of randomization, the two
groups were similar in age, sex, duration of disease before
admission, mean creatinine clearance, mean urinary protein
excretion, presence or absence of hypertension and histological
features (Table 1). The median duration of follow-up was 18
months (3 to 24) for the CsA group and 24 months (12 to 24) for
the control group. One boy, aged 2, stopped CsA on day 60
because of a intercurrent symptomatic urinary tract infection.
After recovery from the infection, his doctor decided not to
restart CsA. This patient was lost to follow-up. A woman, aged
46, stopped CsA after six months because of lack of effect, in
accord with the study protocol. She did not come for the
following visits. The data for both these patients up to their last
visits were considered in the analyses according to the inten-
tion-to-treat principle. Three controls were given corticoster-
oids as rescue treatment, without any effect on proteinuria or
renal function.
The mean trough blood levels of CsA were within the
expected therapeutic window in the first six months for adults
and remained lower than scheduled for children, in spite of
increasing doses (Fig. I).
Changes in proteinuria
During the first year of observation, 13 of 22 patients assigned
to CsA entered either complete or partial remission. One-third
of CsA-treated patients (3 adults and 4 children) attained
complete remission while four other adults and two children
had partial remissions [mean (± SEM) proteinuria from 172.8
18.8 to a minimum of 78.0 26.0 mg/m2/hr at month 6]. In most
cases, the remission occurred within the first month. Only three
adult controls attained partial remissions and none had a
complete remission (Table 2). Thus, the cumulative probability
of obtaining a remission of the nephrotic syndrome within one
year was 0.65 for the CsA group and 0.16 for the control group,
the difference between the two curves being highly significant
(Fig. 2).
Considering only those patients who obtained remission, two
controls had relapses of the nephrotic syndrome within three
months after remission. Of the 13 CsA-treated patients who
obtained remissions, three had relapses of the nephrotic syn-
drome in the third month and six other patients relapsed
between the tenth and the twelfth month, while CsA was being
gradually tapered off. At one year, when CsA was stopped 38%
of patients who had had remissions on CsA were still without
nephrotic syndrome. Of the seven CsA-treated patients who
obtained complete remissions, four (2 adults and 2 children)
remained without proteinuria until the twelfth month, two had
relapses of the nephrotic syndrome in the eleventh and the
twelfth month and one adult had a relapse of nonnephrotic
proteinuria in the seventh month (Table 2).
Eleven patients per group were followed up for two years
after assignment. During the second year of observation, four
patients previously treated with CsA who were in partial or
complete remission at the end of the first year were followed for
a further 9 to 12 months. At the last control visit, one child still
did not have proteinuria, two (one child and one adult) were in
partial remission and one adult had had a relapse of NS. The
control patient (adult) who was in partial remission at the end of
the first year remained in partial remission up to the twenty-
fourth month.
The mean proteinuria, expressed in mg/m2/hr for both adults
and children, had decreased significantly at month 6 for the CsA
group and was unchanged for the control group. However,
when CsA was reduced gradually, proteinuria tended to return
to the baseline values (Fig. 3). It should be noted that for
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Table 1. Characteristics of patients according to renal biopsy at the time of admission
Characteristics
CsA group Control group
FSGS MCD FSGS MCD
N of patients 14 8 14 5
Adults 10 2 9 3
Children 4 6 5 2
Age years
Adults 33.3 13.2 19.0 1.4 43.0 14.7 40.0 11.5
Children 6.5 4.7 6.8 3.5 6.6 1.8 7.5 7.8
Sex mate/female 6/8 7/1 8/6 5/0
Duration of disease
median, years
Adults/children 4.5/0.5 0.5/2.0 1.0/2.0 1.0/1.0
Interstitial lesions
Present-adults/children 6/2 2/0 7/3 1/1
Absent-adults/children 4/2 0/6 2/2 2/1
Vascular lesions
Present-adults/children 2/1 2/0 5/0 3/0
Absent-adults/children 8/3 0/6 4/5 0/2
Obsolescent glomeruli
>50% all glomeruli
Present-adults/children 2/1 0/1 1/2 0/0
Absent-adults/children 8/3 2/5 8/3 3/2
Creatinine clearance
ml/min/1.73 m2
Adults 99.89 35.99 147.80 44.79 99.42 29.36 144.63 79.40
Children 147.95 100.24 164.13 30.09 121.90 30.52 149.60 52.89
Proteinuria mg/m2/hr
Adults 167.15 55.84 115.61 34.06 196.16 159.66 160.57 77.91
Children 220.15 140.33 169.85 109.26 230.46 200.88 113.70 37.00
Hypertension
Present-adults/children 6/0 0/2 5/1 0/0
Absent-adults/children 4/4 2/4 4/4 3/2
Data are means SEM. All 0ther values are numbers of patients unless otherwise indicated . Data for one treated and three control patients who
dropped out of the study during follow-up are not included in this table.
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Fig. 1. Trough blood levels of CsA (means sEM). The means were
within the expected therapeutic window in the first 6 months for adults
(solid line) and remained lower than scheduled for children (dashed
line). Start of reduction of CsA doses (arrow).
patients on CsA who obtained remission, proteinuria dropped
after two weeks (from 167.8 79.6 to 78.7 56.9 mg/m2/hr).
The mixed factorial ANOVA performed on the log-trans-
formed data of proteinuria showed significant differences in the
interaction time * treatments (P < 0.05), the variability between
strata (adults and children) being considered noninfluential.
Univariate analysis showed that no variable among those
investigated (age, sex, duration of the disease, initial creatinine
clearance, initial proteinuria, initial plasma albumin, initial
plasma cholesterol, or histological features of the renal biopsy)
influenced the occurrence of remission.
Changes in renal function
The mixed factorial ANOVA, applied to the log-transformed
data for the renal function parameters (log serum creatinine, log
creatinine clearance), showed no statistically significant differ-
ences at month 6 versus baseline for serum creatinine and
creatinine clearance for the interaction time *treatments, while
the stratum (adults or children) was the influential factor (P <
0.01). In the experimental group, the serum creatinine of one
patient doubled in spite of the early decrease and discontinua-
tion of cyclosporine. With the exclusion of this patient from the
analysis, the mean values of serum creatinine were 67.2 mo1/
liter at baseline and 73.4 mol/liter after 12 months of treat-
ment.
Twenty-two patients, 11 per group, were followed for two
years. Of these, one CsA-treated patient and three controls had
greater than 50% decreases in creatinine clearance, which
occurred between the 18th and 24th months. An additional
patient of the control group had to be placed on regular dialysis
18 months after the start of the study.
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Table 2. Outcome of nephrotic syndrome in 22 CsA-treated patients
Patient
No.
Age
years Sex
Renal
biopsy
Basal
proteinuria
mg/m2/hr
Response to
therapy
Time at
response
mg/,n2/hr
Proteinuria at
response
mg/m2/hr
Outcome
Discontinuation
month 12
After CsA
month 24
1 48 M FSGS 173.4 NS — — NS NS
4 20 F FSGS 240.8 NS — — NS —
5 34 M FSGS 108.4 PR/CR 25/162 12.0/0.0 NS NS
7 22 F FSGS 120.4 NS — — NS —
9 18 M FSGS 151.7 PR 7 14.4 NS NS
15 35 F FSGS 180.6 PR 20 77.1 NS PR
17 46 F FSGS 250.5 PR 15 67.4 — —
20 18 M MCD 92.0 NS — — NS PR
21 27 F FSGS 224.0 PR 60 84.3 NS PR
23 57 M FSGS 108.4 NS — — NS —
26 20 M MCD 139.7 PR/CR 15/300 28.0/4.8 CR CR
28 26 M FSGS 113.2 PR/CR 30/360 72.3/0.0 CR —
42 2 M MCD 186.6 NS — — NS —
48 11 F FSGS 41.0 NS — — NS NS
49 12 F MCD 125.0 PR 30 35.0 PR PR
52 3 F FSGS 364.6 CR 52 0.0 NS —
54 9 M MCD 368.0 NS — — NS —
56 10 F FSGS 185.0 PR 234 26.3 PR NS
57 4 M MCD 96.4 CR 15 0.0 NS CR
60 2 M FSGS 290.0 NS — — — —
61 7 M MCD 185.1 CR 22 0.4 CR —
63 7 M MCD 58.0 CR 15 3.0 CR —
Abbreviations are: M, male; F, female; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; NS, nephrotic syndrome; PR,
partial remission; CR, complete remission.
Time, days
Fig. 2. Cumulative probability of obtaining a remission (complete +
partial) of the nephrotic syndrome within one year. The difference
between curves A (complete + partial remission in CsA-treated group,
—) and C (only partial remission in the control group, ———) is
significant (P < 0.001). Curve B (- - -) represents the cumulative
probability of achieving complete remission within one year in CsA
treated patients. No complete remission was obtained in the control
group.
Changes in other laboratory parameters
In the CsA group there was a significant increase in plasma
albumin and total proteins at six months and a significant
decrease in plasma cholesterol (P < 0.05, paired t-test vs.
basal). These changes tended to be maintained up to the twelfth
month, in spite of CsA tapering off until complete discontinua-
tion. On the other hand, in the CsA group there was also a
significant increase in serum alkaline phosphatase and
azotemia. In both groups, circulating leukocytes decreased,
probably as a consequence of the interruption of prednisone
(Table 3).
Fig. 3. Proteinuria (means SEM) in mg/m2/hr for both adults and
children was significantly decreased at month 6 (P < 0.05) in the CsA
group, and not mod(fled in the control group. When CsA was reduced
gradually (arrow), proteinuria tended to return to the baseline values.
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Side effects
All adverse events that developed in both groups within the
first year were recorded. Five infections (3 children) occurred in
the CsA group and six (3 children) in the control group. Seven
CsA-treated patients complained of gum hyperplasia, three
developed hypertrichosis and four had transient gastric discom-
fort. A mild increase in conjugated bilirubinemia (one case per
group); headache (one case per group); bronchospasm (one
case per group); paresthesia, flushing, epicondylitis, tendinitis
(one case per each symptom in CsA group); extrasystoles and
anemia (one case per each symptom in the control group)
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Table 3. Outcome of some laboratory parameters until month 12 in 22 CsA treated patients and 19 controls
Cyclosporine (N = 22) CycIophosphamide (N = 19)
Basal Month 6 Month 12 Basal Month 6 Month 12
Proteinuria 172.8 18.8 78.0 26.0 136.1 30.1 193.1 36.2 170.0 23.7 157.8 23.6
(mg/m2/hr)-(Lg) (2.184 0.050) (1.415 0.174)a — (2,179 0.071) (2.154 0.064)
Serum creatinine 73.3 7.1 82.1 12.4 107.9 35.4 68.8 6.2 98.7 12.4 95.5 12.4
(pjnol/liter)-(Lg) (1.801 0.044) (1.822 0.062) — (1.808 0.038) (1.927 0.056) —
Creatinine clearance 130.5 12.0 109.3 11.3 117.8 12.3 117.8 9.9 105.1 13.6 100.6 11,1
(ml/min/173 m2)-(Lg) (2.080 0.038) (1.996 0.042) — (2.047 0.033) (1.957 0.056) —
Serum urea (mmol/liter) 11.8 1.6 15.7 31" 12.5 2.2 12.9 1.8 15.0 2.1 13.2 2.5
Serum proteins gluier
Serum albumin gluier
Plasma cholesterol
50.4 1.9
25.4 1.5
0.103 0.008
60.9 2.2"
34,5 18b
0.062 0.007"
57.1 2,6b
31.2 2.3"
0.076 0.008"
52.7 1.6
27.6 1.7
0.089 0.007
51.2 2.5
26.4 1.7
0.094 0.009
51.6 1.7
27.5 1.8
0.094 0.010
mmol/liter
Serum alkaline phosphatase 153.2 21.7 290.5 52.8" 254.7 32.81 128.9 27.3 169.1 40.6 224.2 45.2
U/liter
Leukocytes 109/liter 9.2 0.65 6.7 0.40" 7.0 0.93 10.5 0.91 7,7 0.59a 7.1 0.63a
Data are mean SEM.
ap< 0.05, mixed factorial ANOVA (month 6 vs. basal), time x treatment interactions, performed on log-transformed values of proteinuria, S,
C,. The analysis was performed until month 6, when CsA full doses were administered.
b P < 0.05, paired i-test vs. basal
occurred sporadically. All these symptoms had disappeared
after the first year of observation. In no case did CsA have to be
stopped or even to be reduced by 50% or more.
Blood pressure was checked regularly in both groups. There
were no differences between the two groups at any time, nor
were there any differences between children and adults (data
not shown).
Symptom score
The basal mean symptom scores were 1.5 0.4 for the CsA
group and 1.4 0.2 for the control group. At six months the
score had significantly decreased for the CsA group (0.4 0.2;
P = 0.0017) and was unchanged for the control group (1.2 0.3;
NS).
Discussion
There is not yet a widely accepted treatment for patients with
steroid-resistant INS. Some investigators have reported good
rates of remission for patients with FSGS treated by prolonged
administration of prednisone [17], but others think that continu-
ing to give corticosteroids to steroid-resistant patients is useless
and dangerous [19]. Immunosuppressive agents have been
found to be beneficial by some investigators [20] but a con-
trolled trial did not show any advantage of cyclophosphamide
over corticosteroids in children with FSGS [21]. It has been
claimed that aggressive treatment with methylprednisolone
pulses and cytotoxic agents improves the outcome for patients
with steroid-resistant FSGS [221. Unfortunately, however, no
controlled trial to support the effectiveness of this approach has
been published. In view of the uncertain results of the available
treatments, many clinicians prefer not to persist with steroid
therapy in steroid-resistant patients.
Previous non-controlled trials have shown that about half of
patients with steroid-resistant INS may obtain complete or
partial remission of the nephrotic syndrome on CsA [3—7,
23—28]. However, since CsA can cause vascular and tubuloin-
terstitial lesions [29] and lead to progressive renal dysfunction
[30], there is concern that long-term administration of this drug
might accelerate the evolution to renal failure in patients with
FSGS. There is little information, however, comparing the
outcome of renal function in patients with steroid-resistant INS
given CsA with that in untreated patients.
The aim of this study was to assess the effectiveness and the
safety of CsA in steroid-resistant INS. A main problem has
been definition of steroid resistance. According to the Interna-
tional Study of Kidney Diseases in Children [31], some 90% of
the steroid sensitive children enter remission within four weeks
on prednisone. The response may be later in adults, but most of
patients who respond do so within six weeks [32]. Therefore we
chose to consider as steroid-resistant those children who did
not respond within five weeks and adults who did not respond
within six weeks. We are, however, aware that some few
patients might have responded to more prolonged prednisone
treatment. We gave higher doses of CsA to children than to
adults because pediatric patients have a higher clearance of
CsA [33]. In spite of this, the mean blood concentration
remained lower in children and this might have influenced the
response to treatment. In fact, contrary to what we expected,
the response was similar to or even a bit lower in children than
in adults. Some 60% of patients assigned to CsA obtained
remission of the nephrotic syndrome, which in most cases
persisted while therapeutic doses of CsA were being given. It
was of interest that the proteinuria of the responders decreased
significantly within a few days, and most patients who obtained
remission did so within the first month. On the contrary, only
three control patients had partial remissions of the nephrotic
syndrome and two of them had early relapses. Most studies
have reported that the nephrotic syndrome returned a few days
after CsA was abruptly stopped [3—7, 23—27]. In our trial,
however, in which the drug was tapered off, some 38% of the
responders remained in remission until the twelfth month, and
three of the four followed for 18 to 24 months were still in
remission at the last visit. It is possible that the gradual
reduction of CsA adopted in this protocol instead of abrupt
stopping may have prevented an early relapse into proteinuria
in some patients. No clinical or histological parameter at
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presentation was useful for predicting which patient would
maintain remission.
After this trial was completed, three patients who had com-
plete remission under CsA with relapse of nephrolic syndrome
after stopping the drug asked to again resume CsA. Two
patients again entered complete remission, while the third
patient who had had a renal function deterioration in the
meantime did not show any response in proteinuria or in serum
creatinine.
These data show, therefore, that CsA can improve protein-
uria in a consistent proportion of patients with steroid-resistant
INS. However, patients assigned to CsA had significant in-
creases in plasma albumin and in total proteins and significant
decreases in plasma cholesterol. These changes were particu-
larly evident after six months of therapy, when CsA was being
given at the "full" dose, but persisted even at 12 months, after
gradual tapering off of CsA. Signs and symptoms, as assessed
by the symptom score, had also improved significantly in CsA
patients after six months of therapy.
Patients assigned to CsA showed a slight decline in creatinine
clearance after six months, which was partially reversible when
the CsA dose was reduced. After one year, the mean decrease
in creatinine clearance for the treated group was about 10%, but
this mean includes that patient with rapid renal function decline
because of very severe underlying renal disease. These data
confirm previous retrospective observations showing that,
when given at appropriate doses, CsA can reduce proteinuria in
steroid-resistant patients without causing significant changes in
serum creatinine [12]. After 12 months the control group had a
greater decline in creatinine clearance than the CsA-treated
patients, and this worse renal function in control patients was
confirmed in patients followed for two years, although the
difference between the two groups was not significant.
The use of creatinine clearance to assess the glomerular
filtration rate might be criticized, however. Theoretically, CsA
may interfere with the tubular handling of creatinine and this
would lead to an overestimation of the glomerular filtration rate.
However, a strong correlation between changes in serum cre-
atinine and changes in glomerular filtration rates, as assessed by
inulin clearance or radioisotopic measurements, has been found
in careful studies of patients with autoimmune diseases [34].
Thus, repeated measurements of serum creatinine and/or cre-
atinine clearance can be considered a reliable index for assess-
ing changes in renal function in CsA-treated patients.
We did not perform repeated renal biopsies to evaluate the
possible renal toxicity of CsA and this might be considered a
weak point of the study. This was a deliberate choice, however.
There was agreement among the participating clinicians that in
steroid-resistant patients, who generally have FSGS, it would
have been extremely difficult to recognize whether the devel-
opment or the worsening of tubulointerstitial and microvascular
lesions should be attributed to the natural evolution of the
disease or to CsA toxicity. Moreover, most of us felt it was not
justified ethically to submit them or control patients, for whom
the results of biopsy would not modify the therapeutic policy, to
renal biopsy, which carries a small but substantial risk of
complications [35].
The CsA-related side effects were mild. The incidence of
infections during the follow-up was similar in the two groups.
No significant change in blood pressure was seen and mean
blood pressure values between the two groups did not differ at
any time. Gingival hypertrophy and hypertrichosis occurred
frequently in CsA-treated patients but both disappeared after
the drug was stopped. Therefore, at the doses and for the
duration adopted in this trial, CsA did not produce severe renal
or extra-renal toxicity. It must be pointed out, however, that
our patients were selected on the basis of still having relatively
normal renal function, without severe hypertension.
In conclusion, this controlled study shows that CsA can bring
about remission of the nephrotic syndrome in some 60% of
patients with steroid-resistant INS. In many cases CsA was
effective only while it was being given and relapses into NS
occurred when the drug was discontinued. On the other hand,
since the tolerance of CsA was good in this study, we feel that
for steroid-resistant nephrotic patients with normal renal func-
tion and normal blood pressure, a trial with CsA may be
justified to identify the responders.
Since a response is observed within a few weeks, in most
cases the treatment may be considered ineffective and, there-
fore, interrupted if proteinuria does not improve after three
months of therapy.
For those patients who respond and tolerate well CsA, the
drug might be continued for about one year and then tapered off
along six months or so. If a relapse of nephrolic syndrome
occurs, CsA might be reassumed for another year and then
discontinued again. Before considering further administration,
a careful evaluation of glomerular filtration rate and possibly a
control renal biopsy should be performed.
Acknowledgments
This study was supported in part (drug, organization, Investigators'
meeting) by Sandoz P.F., Milano, Italy. The authors thank: Dr. Maria
Di Gregorio, Dept. of Statistics, Sandoz P.F., Milano, Italy, for
assistance with the statistical analysis and Dr. Bruno M. Cesana,
Epidemiologic Laboratory, Scientific Direction, Ospedale Maggiore,
Milano, Italy, for revising the methodology of the statistical analysis.
Other participants in the Italian multicenter study group were:
Giuliano Mecca, M.D. (Bergamo); Graziella Zacchello, M.D. (Padova);
Giulio A. Cinotti, M.D. (Roma); Enrico Imbasciati, M.D. (Sondrio);
Rosario Maiorca, M.D. (Brescia); and Giuliana Lama, M.D. (Napoli).
Reprint requests to Prof. C. Ponticelli, Divisione di Nefrologia e
Dialisi, Pad. Croff, JRCCS Ospedale Maggiore, Via della Commenda
15, 20122 Milano, Italy.
References
1. HABIB R, GIa&rwIN E, GAGNADOUX MF, HINGLAI5 N, BROYER
M: Immunopathological findings in idiopathic nephrosis: Clinical
significance of glomerular "immune deposits". Pediatr Nephrol
2:402—408, 1988
2. NIAUDET P, HABIB R, GAGNADOUX MF, TETE MJ, BROYER M:
Treatment of severe childhood nephrosis. Adv Nephrol 17:151—172,
1988
3. CAPODICASA G, DE SANTO NG, Nuzzi F, GIORDANO C: Cyclospo-
rifle A in nephrotic syndrome of childhood: A 14-month experience.
mt j Pediatr Nephrol 7:69—72, 1986
4. NIAUDET P, HABIB R, TETE MJ, HINGLAIS N, BROYER M: Cyclo-
sporine in the treatment of idiopathic nephrotic syndrome in
children. Pediatr Nephrol 1:566—573, 1987
5. TEJANI A, BUTT K, TRACHTMAN H, SUTHANITHIRAN M,
ROSENTHAL CJ, KI-IAWAR MR: Cyclosporin-A-induced remission
of relapsing nephrotic syndrome in children. Kidney mt 33:729—734,
1988
6. BRODEHL J, HOYER PF: Cyclosporin in idiopathic nephrotic syn-
drome of children. Am J Nephrol 9(1):61—64, 1989
1384 Pont ice/I i et al: Cyclosporine in steroid-resistant NS
7. MEYRIER A: Cyclosporin in the treatment of nephrosis. Am J
Nephrol 9(l):65—71, 1989
8. MAilER ER, SWENY P, CHAPPEL M, VAROHESE Z, MOORHEAD JE:
Cyclosporin in the treatment of steroid-responsive and steroid-
resistant nephrotic syndrome in adults. Nephrol Dial Transplant
3:728—732, 1988
9. NIAUDET P, BROYER M, HABIB R: Evaluation of nephrotoxicity by
sequential biopsies in 38 children with idiopathic nephrosis treated
with cyclosporin A (CsA). (abstract) Kidney mt 37:260, 1990
10. MEYRIER A: Treatment of glomerular disease with cyclosporin A.
Nephrol Dial Transplant 4:923—931, 1989
11. PONTICELLI C, RIVOLTA E: Cyclosporin in minimal-change glom-
erulopathy and in focal segmental glomerular sclerosis. Am J
Nephrol 10(1):105—109, 1990
12. MILLER C, FEUTREN G, Sd-hEss W, VON GRAFIENRXED B: Serum
creatinine in cyclosporin-induced remission of steroid resistant
nephrotic syndrome (letter). Lancet 2:1352, 1990
13. The 1984 Report of the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure. Arch Intern
Med 144(5):1045—1057, 1984
14. Report of the 2d Task Force on Blood Pressure Control in Chil-
dren—l987. Pediatrics 79(1): 1—25, 1987
15. CHURG J, SOBIN LH: Renal Disease, in Classficaiion and Atlas of
Glomerular Diseases. Tokyo-New York, Igaku-Shoin, 1982
16. DONATSCH P, ABISCH E, HOMBERGER M, TRABER M, Tit M,
VOGES R: A radioimmunoassay to measure cyclosporin A in plasma
and serum samples. Jlmmunoassay 2:19—32, 1981
17, PEI Y, CATTRAN D, DELMORE T, KATZ A, LANG A, RANCE P:
Evidence suggesting under-treatment in adults with idiophatic focal
segmental glomeruloselerosis. Am J Med 82:938—944, 1987
18. KAPLAN EL, MEIER P: Nonparametric estimation from incomplete
observation. JAm Stat Assoc 53:457—481, 1958
19. KLEINKNECHT C, GUBLER MC: Néphrose, in Néphrologie Pédia-
trique, edited by ROYER P, HABIB R, MATHIEU H, BROYER M,
Paris, Flammarion 1983, pp 274—293
20. GEARY DF, FARINE M, THORNER P, BAUMAL R: Response to
cyclophosphamide in steroid resistant focal segmental glomerular
sclerosis: A reappraisal. Clin Nephrol 22:109—113, 1984
21. International Study of Kidney Disease in Children: Cyclophospha-
mide therapy in focal segmental glomerulosclerosis: A controlled
clinical trial. (abstract) Eur J Paediatr 140:149, 1983
22. MENDOZA SA, REZNIK VM, GRIswoLD WR, KRENSKY AM, Y0R-
GIN PD, TUNE BM: Treatment of steroid-resistant focal segmental
glomerulosclerosis with pulse methyiprednisolone and alkylating
agents. Pediatr Nephrol 4:303—307, 1990
23. BRANDIS M, BURGHARD R, LEITITIS J, ZIMMERHACKL B, HILDE-
BRANDT F, HELMCHEN U: Cyclosporine A for treatment of ne-
phrotic syndrome. Transplant Proc 20:275—279, 1988
24. LAGRUE G, LAURENT J, BELGHITI D, ROBEVAR: Cyclosporin and
idiophatic nephrotic syndrome. Lancet ii:692—693, 1986
25. ZIETSE R, WENTING GJ, KRAMER P. MULDER P, SCHALEKAMP
MA, WEIMAR W: Contrasting response to cyclosporin in refractory
nephrotic syndrome. C/in Nephrol 31:22—25, 1989
26. WATSON AR: Cyclosporine therapy for chronic glomerulonephritis.
C/in Nephrol 25:273—274, 1986
27. JAMES RW, BURKE JR, PETRIE JJB, RIOBY RJ, WILLIAMS M:
Cyclosporin A in the treatment of childhood glomerulonephritis.
Aust NZJ Med 19:198—201, 1989
28. WALKER RG, KINCAID-SMITH P: The effect of treatment of corti-
costeroid-resistant idiophatic (primary) focal and segmental hyali-
nosis and sclerosis (focal glomeruloscierosis) with cyclosporin.
Nephron 54:117—121, 1990
29. MIHATSCH MJ, THIEL G, RYFFEL B: Histopathology of cyclospo-
rine nephrotoxicity, in Cyclosporine: Therapeutic Use in Trans-
plantation, edited by KAHAN B, Philadelphia, Grune Stratton,
1986, pp 759—771
30. MYERS BD, SIBLEYR, NEWTON L, TOMLANOVICH SJ, BOSHKOSC,
STINSON E, LUETSCHER JA, WHITNEY DJ, KRASNY D, COPLON
NS: The long-term course of cyclosporine-associated chronic ne-
phropathy. Kidney mt 33:590—600, 1988
31. International Study of Kidney Disease in children: The primary
nephrotic syndrome in children. Identification of patients with
minimal change nephrotic syndrome from initial response to pred-
msone. J Pediatr 98:561—564, 1981
32. NOLASCO F, CAMERON JS, HEYWOOD EF, HICKS J, OGG C,
WILLIAMS DG: Adult-onset minimal-change nephrotic syndrome:
A long-term follow-up. Kidney mnt 29:1215—1223, 1986
33. MOYER PF, OFFNER G, WONtGEIT K, BRODEHL J, PICHLMAYR R:
Dosage of cyclosporin A in children with renal transplants. Clin
Nephrol 22:68—71, 1984
34. MASON J, MOORE LC: Indirect assessment of renal dysfunction in
patients taking cyclosporin A for autoimmune diseases. Br J Derm
122:79—84, 1990
35. WICKRE CU, GOLPER TA: Complications of percutaneous needle
biopsy of the kidney. Am J Nephrol 2:173—178, 1982
